Watson, Amgen team for biosimilars; Epicept takes precaution with Ben Venue-made drug;

> Generics maker Watson Pharmaceuticals ($WPI) and biotech giant Amgen ($AMGN) have announced their foray into the territory of biosimilars, focusing on oncology antibodies. Item

> EpiCept has written European healthcare professionals regarding Ceplene, its leukemia-remission aid manufactured by troubled Ben Venue, reminding them to examine each vial for particles even though regulators have recommended no recall. Item

> A shut-down Pfizer ($PFE) plant in Terra Haute, IN, about 200 miles south of Chicago, is being taken over by an unnamed drugmaker. Story

> The on-again, off-again effort to revive three public vaccine plants in India is on again with the health ministry's approval of $12 million to upgrade one plant--the BCG Lab in Chennai--to WHO manufacturing standards. Item

Xinhuanet reports China will maintain its "iron-handed policy" in fighting counterfeit drugs in the coming year. Report

> AAIPharma Services has named Kevin Flanagan VP for packaging services, overseeing packaging and distribution. Release

> The 245-company-strong pharma manufacturing industry in Bangladesh is plotting to enter U.S. and European markets. Story

> Repligen has acquired Novozymes Biopharma Sweden AB, manufacturer of growth factors used in mammalian cell culture. Release

Suggested Articles

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.

A Chinese OTC drugmaker gets the distinction of ringing in the new year as the first company to be slapped with an FDA warning letter.